Overview
Peptides in Saudi Arabia are treated as pharmaceutical products rather than supplements or unregulated 'research chemicals': anything marketed, sold, imported or dispensed as a medicine must be registered with the Saudi Food and Drug Authority (SFDA), and GLP-1/weight-loss peptides such as semaglutide-class drugs are dispensed only on prescription. Research or compounded peptides that lack SFDA registration (e.g. BPC-157, TB-500, retatrutide) have no lawful retail or personal-import channel, and hormones and growth-hormone products are explicitly barred from postal import. Enforcement is active: in 2026 the Ministry of Health, working with the SFDA, detained gym trainers who were selling unregistered peptides and hormonal drugs traced to a warehouse, and offenders face imprisonment and fines. Personal importation of any medicine requires an SFDA permit supported by a prescription or recent medical report, and narcotic/psychotropic-scheduled medicines additionally require an electronic clearance permit.
Key Points
- In a 2026 enforcement action, the Ministry of Health, coordinating with the Saudi Food and Drug Authority, detained gym trainers for selling and promoting unregistered and unlicensed weight-loss medications, hormonal drugs and peptide substances, with the supply chain traced to a warehouse holding peptide materials and the investigational compound retatrutide. [1]
- Penalties referenced in that peptide/hormone enforcement case include up to six months' imprisonment and significant fines under the law regulating the practice of healthcare professions, in addition to other applicable penalties. [2]
- Pharmaceutical products generally cannot be imported into Saudi Arabia without prior SFDA registration, and importation of an unregistered medicine is discretionary and normally permitted only for urgent need or where no registered alternative exists in the Kingdom. [3]
- Personal importation or clearance of medicines requires an application to the SFDA supported by a prescription or medical report stating the condition, treatment duration and dose, approved by the treating institution and issued no more than six months earlier, plus the patient's identification. [4]
- Medicines containing narcotic or psychotropic substances additionally require an advance electronic clearance permit obtained through the SFDA's Controlled Drugs System (CDS) for travellers entering or leaving the Kingdom. [5]
- Hormones, human growth hormones, steroids and their synthetic versions, along with non-prescription medications and food supplements, are on the official Saudi Post list of items prohibited from entering the Kingdom, which closes the mail-order route commonly used for research peptides. [6]
- In August 2025 the Ministry of Health launched a campaign monitoring the dispensing of weight-loss medications without a prescription, warning the public against medications promoted without a valid prescription and stating that violations by pharmacies or practitioners lead to fines or licence revocation. [7]
- Saudi Arabia maintains statutory schedules of narcotic drugs and psychotropic substances published by the SFDA under the Law of Combating Narcotic Drugs and Psychotropic Substances, but no entry specifically naming research peptides such as BPC-157 or TB-500 was located in the sources reviewed; their unlawful sale and import appears to follow from the general prohibition on unregistered pharmaceuticals rather than from peptide-specific scheduling. [8]